The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV
Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
The Low-PV study is a multicenter, phase II, randomized trial aimed to assess whether the
addition of Pegylated Proline-interferon-alpha-2b to the best therapeutic current strategy
available based on phlebotomies and low dose acetylsalicylic acid (ASA) could improve the
efficacy of treatment of patients with PV at low risk of thrombosis (younger than 60 years
and without prior vascular events), in term of control of recommended level of hematocrit <
45%, over a period of 12 months.